α-1抗胰蛋白酶缺乏症治療市場的成長機會、成長要素、產業趨勢分析、2026-2035年的預測。

2025 年，全球 α-1 抗胰蛋白酶缺乏症治療市場規模預計為 31 億美元，預計到 2035 年將以 8.1% 的複合年成長率成長至 68 億美元。

受α1-抗胰蛋白酶缺乏症（AATD）相關呼吸系統和肝臟疾病盛行率上升、人們對罕見遺傳疾病的認知不斷提高、疾病篩檢計畫不斷擴展以及診斷和治療技術的持續進步等因素的推動，該市場正經歷著穩步成長。 AATD相關慢性呼吸系統和肝臟併發症盛行率的不斷上升，使得對有效疾病管理方案的需求顯著增加。 α1-抗胰蛋白酶是一種在肝臟中合成的天然蛋白質，在保護肺組織免受發炎損傷方面發揮著至關重要的作用。這種蛋白質水平不足會導致嚴重的肺部和肝臟健康併發症，尤其是在其他環境因素加劇疾病進展的情況下。該市場涵蓋了廣泛的治療和管理方法，包括診斷技術、替代療法、基因標靶治療策略、吸入療法和支持性護理方案。生物技術和精準醫學的持續創新進一步推動了旨在改善患者預後並應對α1-抗胰蛋白酶缺乏症相關長期挑戰的先進治療方案的開發。

α1-抗胰蛋白酶缺乏症治療市場正受益於疾病識別和治療性介入的顯著進展。醫護人員和患者對該疾病的認知不斷提高，加速了早期診斷和治療的啟動，有助於改善疾病管理。對個人化醫療的日益重視推動了標靶治療的引入，這些療法旨在解決疾病的根本原因並延緩其進展。此外，生物製藥、基因療法和新型治療平台的進步也為整個治療領域的創新創造了新的機會。醫療服務提供者繼續致力於制定全面的疾病管理策略，旨在減少併發症、維持器官功能並提高患者的生活品質。預計這些趨勢將在整個預測期內支撐整個市場的持續成長。

到2025年，藥物治療領域的市場規模將達到22億美元。該領域在控制疾病症狀、延緩臨床進展以及最大限度減少呼吸系統和肝臟相關併發症發揮核心作用。藥物治療的廣泛應用反映了α1-抗胰蛋白酶缺乏症常見肺部疾病所帶來的沉重負擔。藥物療法被廣泛用於改善呼吸功能、輔助疾病管理並提升患者的整體健康水平。藥物治療的不斷進步正在進一步鞏固該領域在市場中的地位。

預計到2035年，腸外給藥領域將以8%的複合年成長率成長。該領域的強勁發展勢頭歸功於腸外給藥能夠將治療藥物直接輸送到體循環，從而確保最佳的治療效果。在α1-抗胰蛋白酶缺乏症的治療領域，靜脈注射替代療法仍是主要的治療方法。這種給藥途徑之所以被廣泛接受，是因為它能夠維持體內適當的蛋白質濃度，減輕進行性性組織損傷，並支持疾病的長期管理。隨著治療方案的不斷發展，腸外給藥領域預計仍將是患者照護中至關重要的組成部分。

預計到2025年，北美α1-抗胰蛋白酶缺乏症治療市場將佔據60.2%的佔有率，並繼續保持主導地位。該地區的成長得益於先進基因檢測技術的廣泛應用、對罕見呼吸系統疾病的高度關注以及專業治療方法的普及。成熟的生物製藥公司、強大的血漿採集能力和完善的輸液治療基礎設施，都為患者獲得持續治療提供了保障。與α1-抗胰蛋白酶缺乏症相關的呼吸系統疾病盛行率的上升，以及精準醫療方法的日益普及，正在推動全部區域市場需求的持續成長。這些因素共同鞏固了北美在全球市場的主導地位。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章 行業洞察

• 產業生態系分析
• 影響產業的因素
  • 促進因素
    • α1-抗胰蛋白酶缺乏症（AATD）盛行率增加
    • 生物技術進展
    • 核准一種治療AATD的新治療方法
    • 罕見疾病保險覆蓋範圍和保單的改進
  • 產業潛在風險與挑戰
    • 高昂的醫療費用
    • 與治療相關的不利事件
  • 市場機遇
    • 基因治療和生物製藥領域的進展
    • 擴大宣傳活動和早期診斷計劃
• 成長潛力分析
• 監理情勢
• 管道分析
• 人工智慧和生成式人工智慧對市場的影響
• 流行病學和患者人群分析
• 未來市場趨勢
• 波特的分析
• PESTLE分析

第4章 競爭情勢

• 介紹
• 企業市佔率分析
  • 北美洲
  • 歐洲
  • 亞太地區
• 企業矩陣分析
• 主要市場公司的競爭分析
• 競爭定位矩陣
• 主要進展
  • 併購
  • 夥伴關係和聯盟
  • 新產品發布
  • 業務拓展計劃

第5章 市場估計與預測：依治療類型分類，2022-2035年

• 藥物
  • α-1蛋白酶抑制劑
  • 支氣管擴張劑
  • 皮質類固醇
  • 其他藥物
• 治療方法
  • 輔助性治療
  • 氧氣療法
  • 其他療法
• 外科手術

第6章 市場估計與預測：依給藥途徑分類，2022-2035年

• 腸外
• 鼻內
• 口服

第7章 市場估計與預測：依年齡層別分類，2022-2035年

• 兒童
• 成人

第8章 市場估算與預測：依最終用途分類，2022-2035年

• 醫院
• 專科診所
• 其他最終用戶

第9章 市場估計與預測：依地區分類，2022-2035年

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • UAE

第10章：公司簡介

• Manufacturers
  • CSL Behring
  • Grifols
  • Takeda Pharmaceutical
  • Kamada
  • LFB Biotechnologies
• 管道/新興企業
  • Prime Medicine
  • Jaguar Gene Therapy
  • Intellia Therapeutics
  • Inhibrx
  • Arrowhead Pharmaceuticals
  • Octapharma
• Service providers
  • The Johns Hopkins Hospital
  • The General Hospital
  • National Jewish Health

The Global Alpha-1 Antitrypsin Deficiency Disease Treatment Market was valued at USD 3.1 billion in 2025 and is estimated to grow at a CAGR of 8.1% to reach USD 6.8 billion by 2035.

The market is experiencing steady expansion due to the increasing incidence of alpha-1 antitrypsin deficiency (AATD)-related respiratory and liver conditions, growing recognition of rare genetic disorders, expanding disease screening programs, and ongoing progress in diagnostic and therapeutic technologies. The rising prevalence of chronic respiratory and hepatic complications associated with AATD is creating significant demand for effective disease management solutions. Alpha-1 antitrypsin is a naturally occurring protein synthesized by the liver that plays a vital role in protecting lung tissue from inflammatory damage. Insufficient levels of this protein can result in serious pulmonary and liver-related health complications, particularly when additional environmental factors contribute to disease progression. The market encompasses a broad range of treatment and management approaches, including diagnostic technologies, augmentation therapies, gene-focused therapeutic strategies, inhalation-based treatments, and supportive care solutions. Continuous innovation in biotechnology and precision medicine is further supporting the development of advanced treatment options designed to improve patient outcomes and address the long-term challenges associated with alpha-1 antitrypsin deficiency disease.

The alpha-1 antitrypsin deficiency disease treatment market is benefiting from significant advances in disease identification and therapeutic intervention. Increasing awareness among healthcare professionals and patients is encouraging earlier diagnosis and treatment initiation, contributing to improved disease management. The growing emphasis on personalized healthcare approaches is supporting the adoption of targeted therapies that address the underlying causes and progression of the disorder. In addition, advancements in biologics, genetic medicine, and novel therapeutic platforms are creating new opportunities for innovation across the treatment landscape. Healthcare providers continue to focus on comprehensive disease management strategies aimed at reducing complications, preserving organ function, and enhancing quality of life for affected individuals. These developments are expected to support sustained growth across the market over the forecast period.

The medication segment generated USD 2.2 billion in 2025. This segment plays a central role in managing disease symptoms, slowing clinical progression, and minimizing complications associated with both respiratory and hepatic manifestations of the condition. The widespread use of pharmacological therapies reflects the significant burden of pulmonary disorders commonly associated with alpha-1 antitrypsin deficiency. Medication-based treatment approaches are widely utilized to improve respiratory function, support disease management, and enhance overall patient well-being. Continued advancements in pharmaceutical therapies are further strengthening the segment's position within the market.

The parenteral segment is anticipated to grow at a CAGR of 8% throughout 2035. The strong position of this segment is attributed to the effectiveness of parenteral administration in delivering therapies directly into systemic circulation, ensuring optimal therapeutic outcomes. Within the alpha-1 antitrypsin deficiency treatment landscape, augmentation therapies delivered through intravenous administration remain a primary treatment approach. This route of administration is widely preferred due to its ability to maintain appropriate protein levels within the body, helping reduce progressive tissue damage and support long-term disease management. As treatment protocols continue to evolve, the parenteral segment is expected to remain a critical component of patient care.

North America Alpha-1 Antitrypsin Deficiency Disease Treatment Market accounted for 60.2% share in 2025, maintaining its position as the leading regional market. Growth across the region is supported by broad access to advanced genetic testing technologies, strong awareness of rare respiratory disorders, and widespread adoption of specialized treatment options. The presence of established biopharmaceutical companies, extensive plasma collection capabilities, and robust infusion therapy infrastructure contributes to consistent treatment accessibility. Rising prevalence of respiratory conditions associated with alpha-1 antitrypsin deficiency, combined with the increasing adoption of precision medicine approaches, continues to strengthen market demand throughout the region. These factors collectively reinforce North America's leadership within the global market.

Key companies operating in the Global Alpha-1 Antitrypsin Deficiency Disease Treatment Market include Takeda Pharmaceutical, Grifols, CSL Behring, Kamada, LFB Biotechnologies, Intellia Therapeutics, Prime Medicine, Arrowhead Pharmaceuticals, Inhibrx, Jaguar Gene Therapy, Octapharma, National Jewish Health, The Johns Hopkins Hospital, and The General Hospital. Companies participating in the alpha-1 antitrypsin deficiency disease treatment market are implementing a variety of strategies to strengthen their market position and expand their competitive advantage. Significant investments in research and development remain a primary focus as organizations work to advance innovative therapies, including gene-based treatments, biologics, and precision medicine solutions. Strategic collaborations with research institutions, healthcare organizations, and biotechnology companies are accelerating product development and clinical advancement. Many companies are also expanding their clinical trial programs to evaluate new therapeutic approaches and improve treatment effectiveness. In addition, businesses are prioritizing geographic expansion, regulatory approvals, and enhanced patient access initiatives to broaden their market reach. Strengthening manufacturing capabilities, improving treatment availability, and investing in advanced diagnostic technologies are further helping market participants reinforce their presence and secure long-term growth within the global alpha-1 antitrypsin deficiency disease treatment industry.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research approach
• 1.3 Quality commitments
  • 1.3.1 GMI AI policy and data integrity commitment
    • 1.3.1.1 Source consistency protocol
• 1.4 Research trail and confidence scoring
  • 1.4.1 Research trail components
  • 1.4.2 Scoring components
• 1.5 Data collection
  • 1.5.1 Partial list of primary sources
• 1.6 Data mining sources
  • 1.6.1 Paid sources
    • 1.6.1.1 Sources, by region
• 1.7 Base estimates and calculations
  • 1.7.1 Revenue share analysis
  • 1.7.2 Base year calculation
• 1.8 Forecast model
• 1.9 Research transparency addendum
  • 1.9.1 Source attribution framework
  • 1.9.2 Quality assurance metrics
  • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Treatment type trends
  • 2.2.3 Route of administration trends
  • 2.2.4 Age group trends
  • 2.2.5 End use trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of alpha-1 antitrypsin deficiencey disease (AATD)
    • 3.2.1.2 Advancements in biotechnology
    • 3.2.1.3 Approval of novel therapies for AATD
    • 3.2.1.4 Improving reimbursement coverage and rare disease policies
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of treatment
    • 3.2.2.2 Adverse effects associated with treatment
  • 3.2.3 Market opportunities
    • 3.2.3.1 Advancement in gene therapy and biologics
    • 3.2.3.2 Increasing awareness and early diagnosis programs
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape (Driven By Primary Research)
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East and Africa
• 3.5 Pipeline analysis (Driven By Primary Research)
• 3.6 Impact of AI and Generative AI on the market (Driven By Primary Research)
• 3.7 Epidemiology and patient population analysis (Driven By Primary Research)
• 3.8 Future market trends (Driven By Primary Research)
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 North America
  • 4.2.2 Europe
  • 4.2.3 Asia Pacific
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2022-2035 ($ Mn)

• 5.1 Key trends
• 5.2 Medication
  • 5.2.1 Alpha-1 proteinase inhibitor
  • 5.2.2 Bronchodilators
  • 5.2.3 Corticosteroids
  • 5.2.4 Other medications
• 5.3 Therapy
  • 5.3.1 Augmentation therapy
  • 5.3.2 Oxygen therapy
  • 5.3.3 Other therapies
• 5.4 Surgery

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2022-2035 ($ Mn)

• 6.1 Key trends
• 6.2 Parenteral
• 6.3 Intranasal
• 6.4 Oral

Chapter 7 Market Estimates and Forecast, By Age Group, 2022-2035 ($ Mn)

• 7.1 Key trends
• 7.2 Pediatric
• 7.3 Adult

Chapter 8 Market Estimates and Forecast, By End Use, 2022-2035 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Specialty clinics
• 8.4 Other end users

Chapter 9 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia-Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Manufacturers
  • 10.1.1 CSL Behring
  • 10.1.2 Grifols
  • 10.1.3 Takeda Pharmaceutical
  • 10.1.4 Kamada
  • 10.1.5 LFB Biotechnologies
• 10.2 Pipeline/emerging players
  • 10.2.1 Prime Medicine
  • 10.2.2 Jaguar Gene Therapy
  • 10.2.3 Intellia Therapeutics
  • 10.2.4 Inhibrx
  • 10.2.5 Arrowhead Pharmaceuticals
  • 10.2.6 Octapharma
• 10.3 Service providers
  • 10.3.1 The Johns Hopkins Hospital
  • 10.3.2 The General Hospital
  • 10.3.3 National Jewish Health